Nexera Pharma has entered into an exclusive license agreement for a GPCR-targeted program with a venture company established by a European VC, acquiring shares in the company and rights to receive milestone and royalty payments.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4565","jir_company_name":"Nexera Pharma Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4565-20260212-01.pdf","jir_short_summary":"Nexera Pharma has entered into an exclusive license agreement for a GPCR-targeted program with a venture company established by a European VC, acquiring shares in the company and rights to receive milestone and royalty payments.","jir_summary":"### Overview of the License Agreement\nNexera Pharma Corporation has concluded an exclusive license agreement for a GPCR-targeted program with a venture company established by a prominent European venture capital firm. Under the contract, Nexera Pharma is granted rights for development, manufacturing, and commercialization worldwide excluding Japan and parts of the Asia-Pacific region, while simultaneously acquiring shares in the venture company. The company also has rights to receive milestone rewards and royalties based on sales; however, the detailed terms of the agreement are undisclosed.\n\n### Outlook and Impact\nThrough this agreement, Nexera Pharma aims to maximize the value of the GPCR-targeted program by partnering with an overseas partner possessing development promotion capabilities and funding functions. Nexera Pharma may also participate in the company\u2019s planned Series A funding round alongside the overseas VC. The impact on the consolidated results for the fiscal year ending December 2026 is currently under review, and any matters requiring disclosure will be promptly announced.","jir_financial_highlights":"Milestone and royalty payments under the agreement: Unknown (Details undisclosed)\nImpact on consolidated results for the fiscal year ending December 2026: Unknown (Under review)\nAcquisition of shares in the company: Unknown (Unknown)","jir_category":"","jir_hashtags":"#NexeraPharmaCorporation, #M&A_and_CapitalAlliance, #JapaneseStocks","jir_key_figures":"Agreement Date: 2026-02-12\nTarget Program: GPCR-targeted program (exclusive license worldwide excluding Japan and parts of APAC)\nImpact on FY2026 Results: Under review","jir_meta_title":"Nexera Pharma Announces Exclusive License Agreement and Share Acquisition for GPCR-Targeted Program","jir_meta_description":"Nexera Pharma has entered into an exclusive license agreement with a European venture company for a GPCR-targeted program, acquiring shares and rights to milestone and royalty payments. The impact on fiscal 2026 results is under review.","jir_og_title":"Nexera Pharma Announces License Agreement for GPCR-Targeted Program","jir_og_description":"Nexera Pharma has signed an exclusive license agreement regarding a GPCR-targeted program with a European venture company and plans to acquire shares as well. The impact on financial results is currently under review.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16880,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-28480","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n